Daniel K. Hall‐Flavin
Mayo Clinic(US)Mayo Clinic in Arizona(US)
Publications by Year
Research Areas
Alcohol Consumption and Health Effects, Substance Abuse Treatment and Outcomes, Treatment of Major Depression, Pharmacogenetics and Drug Metabolism, Tryptophan and brain disorders
Most-Cited Works
- → Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting(2013)203 cited
- → Psychological effects of the COVID 19 pandemic on healthcare workers globally: A systematic review(2020)192 cited
- → Using a pharmacogenomic algorithm to guide the treatment of depression(2012)182 cited
- → The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response(2015)139 cited
- → Substance Use Disorders and Telehealth in the COVID-19 Pandemic Era(2020)129 cited
- → TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics(2016)118 cited
- → Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes(2015)111 cited
- → Alcohol Craving as a Predictor of Relapse(2012)102 cited
- → The Role of Gabapentin in the Management of Alcohol Withdrawal and Dependence(2015)95 cited
- → Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons(2019)94 cited